The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches Authors: Sanaz Ahmadi Ghezeldasht, Raheleh Miri, Seyed Khosrow Shamsian, Arman Mosavat, Seyed Abdolrahim Rezaee Published: 2026 ABSTRACT AbstractThe human T-cell leukaemia virus type 1 (HTLV-1) is an oncogenic retrovirus responsible for severe diseases, including adult T-cell leukaemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite its significant global prevalence, specific direct-acting antiviral therapies remain unavailable. This review comprehensively surveys the HTLV-1 protease (HTLV-1 PR), a pivotal homodimeric aspartic protease essential for viral maturation and infectivity, as a critical antiviral drug target.​ A detailed analysis of HTLV-1 PR's narrow substrate specificity, influenced by specific subsite interactions, highlights its distinction from the human immunodeficiency virus-1 protease (HIV-1 PR) and explains the limited efficacy of cross-targeting existing HIV-1 inhibitors. The review critically assesses current inhibitor development strategies, including the challenges posed by its unique structural architecture and the need for novel, HTLV-1-specific chemical scaffolds. We discuss the promise of structure-based drug design, in silico screening, and combinatorial chemistry in overcoming these hurdles, aiming to accelerate the discovery of potent and selective HTLV-1 PR inhibitors. This work consolidates knowledge on HTLV-1 PR, identifies key challenges, and proposes future research directions, ultimately contributing to the urgent need for effective therapeutic interventions against HTLV-1 infection.Keywords: HTLV-1 anti-protease, HTLV-1 protease (HTLV-1 PR), HTLV-1-Associated diseases, Human T-cell leukaemia virus type 1 (HTLV-1) Introduction Human T-cell leukaemia virus type 1 (HTLV-1) is a retrovirus that can cause adult T-cell leukaemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [[1], [2], [3]]. With an estimated 5-20 million infected individuals globally, the need for effective therapies is urgent [4]. In contrast to the therapeutic approaches available for HIV-1, there are presently no direct-acting antiviral agents or vaccines established for HTLV-1, underscoring a critical demand for novel therapeutic advancements in this domain. This critical demand is further highlighted by the limitations of current treatment options for HTLV-1-associated diseases, which are often palliative or rely on broad-spectrum antivirals with limited efficacy, underscoring the urgent need for novel, targeted approaches [5]. HTLV-1 PR, an essential aspartic acid protease in the HTLV-1 life cycle, plays a pivotal role in viral replication and maturation [4]. Unlike HIV-1, where protease and polymerase are encoded by a shared reading frame [6], HTLV-1 PR is encoded by a specific reading frame in the HTLV-1 genome. Structurally, it is a homodimeric protease, similar to other retroviral proteases, with each monomer comprising approximately 125 amino acids. It exhibits 28% sequence identity with HIV-1 PR and 45% identity at the active-site residues, suggesting unique three-dimensional conformations that highlight its potential as a therapeutic target [5,7]. The presence of two crucial aspartate residues in its catalytic dyad indicates its functional specificity in cleaving polyproteins into their mature forms, which are vital for virus assembly, including Gag, Pro, and Env [8,9]. In common with other retroviruses, the full-length mRNA encodes the gag polyprotein (p55). The viral protease processes this polyprotein into smaller structural proteins: the matrix (MA, p19), the capsid (CA, p24), and the nucleocapsid (NC, p15) [10]. The gene encoding the protease is located at the junction between the 3′ end of gag and the 5′ end of pol, and its expression relies on a ribosomal frameshift mechanism to produce the functional enzyme. The expression and activation of the protease are precisely regulated by frameshifting during polyprotein translation. This mechanism guarantees the proper stoichiometry of viral enzymes throughout the viral life cycle [11]. Anti-protease strategies targeting HTLV-1 may contribute to controlling HTLV-1–associated diseases by impairing viral particle maturation and reducing infectivity. Although HTLV-1 primarily spreads through clonal expansion, limiting cell-to-cell transmission could reduce the formation of new infected clones, which is associated with higher proviral load and increased risk of ATLL and HAM/TSP. Additionally, protease inhibition may alter the processing of viral proteins involved in pathogenic immune activation. While unlikely to be curative on their own, these approaches could complement therapies aimed at reducing viral burden and disease progression [4,12]. This review provides a comprehensive overview of the molecular functions, structural determinants, and current strategies for inhibitor design targeting the HTLV-1 PR. In doing so, it brings together experimental findings, structural characterisations, and emerging methodologies to clarify the challenges and potential solutions for developing effective antiviral therapies against HTLV-1. An exact understanding of the molecular and enzymatic functions of HTLV-1 PR is crucial for identifying its unique vulnerabilities and thereby addressing a key challenge in developing effective antiviral therapies for HTLV-1-associated diseases. Molecular and enzymatic properties HTLV-1 PR plays a critical role during the viral life cycle by processing the Gag and Gag-Pro-Pol polyprotein precursors. This proteolytic processing is a vital step in virion maturation, ensuring the production of mature, infectious viral particles [13]. Like other retroviral proteases, HTLV-1 PR relies on two conserved aspartates in the D-T/S-G-A motif of its active site [14]. However, its narrower substrate specificity, resulting from subtle structural differences in its binding pocket, allows it to process distinct cleavage sites essential for virion assembly [13]. These aspartates bind and activate a water molecule, which then acts as a nucleophile during the hydrolysis of peptide bonds within viral polyprotein substrates [15]. The enzyme operates optimally at physiological temperature (37 °C), similar to other retroviral proteases [16]. Key elements, such as pH, temperature, and ionic strength, are recognised as influencing protease activity. Research has shown that even slight changes in environmental conditions can lead to significant variations in enzymatic performance [16]. HTLV-1 PR operates as a mandatory homodimer, with both monomers providing key residues for substrate recognition and catalysis. The enzyme consists of two elongated, curved subunits that create a central active site containing conserved Asp32 residues, which are vital for the catalytic process. Surrounding residues, such as Arg10, Lys95, and Asn96, facilitate substrate binding, generating multiple pockets (S1, S2, S3, and S1', S2', S3') on either side of the cleavage site [17]. The catalytic process begins with substrate binding to a well-defined cleft between the two monomers, followed by conformational adjustments to optimise active site geometry for nucleophilic attack [18]. Quantum mechanics/molecular mechanics (QM/MM) simulations highlight the roles of active-site protonation and conformational flexibility in catalysis and substrate turnover, enabling the cleavage of Gag and Gag-Pol precursors, which are vital for viral maturation [10]. This aspartic protease mechanism is highly dependent on the precise three-dimensional alignment of catalytic residues and the bound substrate, which is only possible in the enzyme's dimeric form [19]. Table 1 shows the structural and functional components of the HTLV-1 PR. Table 1The structural and functional components of HTLV-1 PR.Table 1Structural featureRole in enzymatic functionHomodimeric architectureForms a central active site, essential for activityCatalytic Asp32 DyadActivates water, executes peptide bond hydrolysisSubstrate-binding sitesConfer substrate specificity (S1/S2/S3, S1'/S2'/S3')C-terminal residuesStabilise dimer, essential for catalysis The structural and functional components of HTLV-1 PR. Kinetic properties and catalytic efficiency HTLV-1 PR is active under acidic conditions, with kinetic studies revealing parameters such as the Km and catalytic efficiency (kcat/Km). Using peptide substrates mimicking natural cleavage sites (MA/CA and CA/NC), the Km values were 101.3 ± 1.9 μM and 31.6 ± 5.9 μM, respectively, indicating competent enzyme activity. The catalytic rate is substrate-dependent, with higher efficiency observed for MA/CA cleavage [5]. The enzyme can rapidly and specifically process immature viral particles, with the correct cleavage being a prerequisite for morphological maturation and infectivity [20]. HTLV-1 PR has been chemically synthesised, and its proteolytic activity has been tested using oligopeptide substrates derived from various retroviral polyproteins. Cleavage of an oligopeptide representing the HTLV-1 retroviral processing site P19/24 (APQVLPVMHPHG) by HTLV-1 PR yielded Km and kcat values of 470 μM and 0.184 s−1, respectively. For the P24/15 (KTKVLVVQPK) processing site, Km and kcat values were 310 μM and 0.0060 s−1, respectively. The ability of HTLV-1 PR to cleave the substrate (APQVLNphVMHPL) was improved when the P1' proline of P19/24 was replaced with p-nitro-phenylalanine (Nph). Truncated forms of HTLV-1 PR (116-, 121-, and 122- residue) showed similar catalytic efficiency constants (kcat/Km), indicating that the C-terminal amino acids are not essential for full activity [21]. Regulatory mechanisms of HTLV-1 PR The HTLV-1 PR is encoded by the pol gene and is expressed when the viral genome's long terminal repeat (LTR) promoter is activated by the Tax protein, which enhances transcription of all viral genes, including gag, pol, and env [22]. While Tax activates HTLV-1 gene transcription and supports viral replication, and HBZ promotes leukemogenesis in HTLV-1-infected cells, neither has been shown to regulate protease mRNA, protein, or enzyme activity [23]. Another critical regulatory protein, Rex, regulates post-transcriptional processing and transport of viral mRNAs by binding to the Rex response element (RxRE) in their 3' untranslated region (UTR), enabling export and stabilisation of unspliced and singly spliced transcripts for gag, pol (including protease), and env. This transport is crucial for protease expression, preventing mRNA retention and nuclear degradation [24]. Therefore, the genetic regulation of HTLV-1 PR is primarily orchestrated through coordinated transcriptional control by Tax and post-transcriptional processing by Rex. Structural and biochemical analyses have primarily focused on the enzymatic properties and inhibitor binding of HTLV-1 PR; however, potential post-translational modifications such as phosphorylation or ubiquitination that could control its stability or activity remain largely uninvestigated or unreported, representing a current limitation in our mechanistic understanding. HTLV-1's replication is complex but does not involve protease-based feedback or autoregulation mechanisms [25]. This absence underscores the compartmentalisation of protease function to the post-translational phase of viral replication—specifically, polyprotein processing and maturation—without upstream feedback onto earlier regulatory events. Other regulatory mechanisms of HTLV-1 PR function are summarised in Table 2. Table 2Regulatory mechanisms of HTLV-1 PR function.Table 2Regulatory levelMechanismImpact on proteaseTranscriptionalLTR activated by Tax, allowing pol expressionIndirectPost-transcriptionalRex-mediated export of gag-pol mRNAEssentialTemporal kinetics“Two-phase” expression pattern via Tax/Rex dynamicsIndirectPost-translational modificationsNo well-characterised PTMs reportedNoneProtein-Protein interactionsNo direct modulation by Tax, HBZ, or accessory proteinsNonePolyprotein processingDimerisation and autocatalytic cleavageEssentialHost cellular or environmentalNo direct host/stress regulation establishedNone or minimalFeedback/AutoregulationNo feedback loops involving the proteaseNoneTherapeutic inhibitorsDirect enzyme inhibition by small moleculesBlock activityThe two-phase expression pattern of HTLV-1 is defined by the early accumulation of regulatory tax/rex mRNA followed by a Rex-dependent phase where structural and enzymatic transcripts, including those encoding the HTLV-1 PR, are expressed. ​While host environmental stress factors can trigger a burst in viral transcription, current evidence suggests that direct host-linked regulation specifically targeting the protease enzyme itself is minimal or not yet fully characterized. Regulatory mechanisms of HTLV-1 PR function. The two-phase expression pattern of HTLV-1 is defined by the early accumulation of regulatory tax/rex mRNA followed by a Rex-dependent phase where structural and enzymatic transcripts, including those encoding the HTLV-1 PR, are expressed. ​While host environmental stress factors can trigger a burst in viral transcription, current evidence suggests that direct host-linked regulation specifically targeting the protease enzyme itself is minimal or not yet fully characterized. HTLV-1 PR substrate specificity and structural determinants HTLV-1 PR exhibits narrow substrate specificity, relying on conserved motifs and amino acid context [13]; most critical are P1 and P1' positions, but activity is highly dependent on subsite interactions extending to P4 and P4 [26]. This situation contrasts with HIV-1 PR, which tolerates greater diversity in substrate sequences, reflecting evolutionary specialisation in HTLV-1 [27]. This contrasts with HIV-1 PR, which tolerates greater diversity in substrate sequences, reflecting evolutionary specialisation in HTLV-1, a phenomenon rooted in distinct co-evolutionary pressures and structural constraints, thereby highlighting the novel challenge in designing effective HTLV-1 inhibitors [28]. The enzyme's substrate specificity is defined by both direct contacts and long-range conformational networks connecting various regions of the protease [29]. Detailed mutational studies involving substrate analogues and recombinant proteases have demonstrated that specific residues within the binding pocket—particularly those at S3 and flanking subsites—determine the efficiency and sequence selectivity of cleavage. The protease's ability to process only a limited range of substrates makes it less tolerant to mutations without compromising viral fitness, in contrast to the higher adaptability of lentiviral proteases such as HIV-1 [13]. When compared to other retroviral proteases, such as bovine leukaemia virus (BLV) protease, HTLV-1 PR's specificity is closer to BLV than to HIV-1 or murine leukaemia virus proteases [27]. This specificity is believed to arise from conserved residue interaction networks within the structure, in which any local perturbation can affect global conformational dynamics and substrate interactions [29]. Notably, the enzyme's unique structural features, such as the lower mobility of the flap regions compared to those of its HIV counterpart, confer distinct substrate specificity. This difference contributes to the lack of efficacy of many HIV protease inhibitors against HTLV-1 PR, highlighting the necessity for the development of targeted therapeutic agents [30,31]. Studies indicate that while some HIV protease inhibitors, such as Indinavir, exhibit low micromolar affinity for HTLV-1 PR, their efficacy remains suboptimal, primarily due to less favourable interactions arising from crucial amino acid differences in the flap regions [32]. HTLV-1 PR structural studies and molecular modelling X-ray crystallography and molecular dynamics simulations are crucial for understanding the structure of HTLV-1 PR. X-ray crystallography provides precise representations of the protease-inhibitor complex, focusing on key active sites, such as flexible flaps, which are crucial for understanding enzyme function and the development of potential therapies. Molecular dynamics simulations reveal how these regions move over time, where even minor shifts in flap orientation can significantly affect substrate recognition and binding affinity during binding, catalysis, and release [18,31,32]. The conserved aspartate residues in the active site are central to catalysis, but key residues lining the binding pocket—often aromatic or hydrophobic—work in concert with flexible residues in the flaps to stabilise bound substrates or inhibitors [8]. Unique insertions and subtle sequence variations immediately adjacent to the flaps contribute to distinct motion profiles not seen in other retroviral proteases [31]. Table 3 highlights the molecular distinctions that make the HTLV-1 PR both a challenging and an attractive target for the development of antiviral therapies. Table 3Comparative analysis of molecular functions and catalytic properties between HTLV-1 and HIV-1 PRs.Table 3ParameterHTLV-1 PRHIV-1 PRStructureHomodimeric aspartyl protease with 125 residues/monomerHomodimeric aspartyl protease with ∼99 residues/monomerCatalytic mechanismUses a pair of aspartic acid residues to hydrolyse peptide bondsSimilar mechanism with two aspartic acid residuesSubstrate specificityNarrow substrate specificity, highly sensitive to mutations, prefers Leu at P1.Broader substrate specificity increases adaptabilityP1 position preferenceLeucineValine, phenylalanine, othersS1 pocket toleranceLow for β-branched residuesHigherDimerisation roleEssential, C-term stabilisationEssential, less C-term dependenceFlap contributionModulates access and specificityHighly dynamic, broader accessEnvironmental sensitivityStrongly influenced by pH, temperature, and ionic strengthLess pronounced sensitivity in catalytic performance Comparative analysis of molecular functions and catalytic properties between HTLV-1 and HIV-1 PRs. The supervised molecular dynamics (SuMD) technique reveals the significance of specific interactions, such as salt bridges between the inhibitor's functional groups (e.g., pyrrolidine) and critical protease residues (Asp32/Asp32′). It highlights the supportive roles played by other residues, such as His66′ [8]. High-resolution structures of the protease complexed with inhibitors not only map contact points but also reveal that differences in flap orientation can alter water-mediated networks and the formation/disruption of key hydrogen bonds, directly impacting binding affinity [17]. Experimental evidence of HTLV-1 PR mutation studies Mutagenesis has clarified the essential, non-redundant roles of key residues in all major structural domains of the HTLV-1 PR [33]. Even minor changes impart pronounced effects on enzymatic activity, substrate specificity, dimer integrity, and inhibitor sensitivity, attesting to the enzyme's finely tuned structure-function relationship. While BLV and HIV-1 PRs can often sustain various substitutions in binding pockets and flaps without catastrophic loss of function, parallel mutations in HTLV-1 frequently lead to enzymatic inactivation. These differences inform our understanding of evolutionary divergence among retroviral proteases and guide selective antiviral drug development strategies [34]. Studies have shown that nearly all single and multiple HTLV-1 PR mutants, particularly those targeting the substrate-binding residues, exhibit significant reductions in both catalytic efficiency and proper folding. C-terminal deletions, even by five amino acids, destabilise the dimer and significantly reduce enzyme activity—causing 4–40-fold decreases with five residues lost and complete inactivation with ten [21]. This sensitivity is attributed to a unique hydrophobic tunnel at the dimer interface formed by the C-terminal residues, a structural feature absent in HIV-1 PR. These findings establish the critical role of the terminal sequences in both dimer stabilisation and overall protease functionality [5]. The leucine-to-isoleucine mutation at position 40 (L40I) has practical implications for stabilising protease constructs during experiments by reducing autoproteolytic degradation, which otherwise complicates structural and kinetic analyses [35]. The enzyme's inability to tolerate mutations indicates a highly optimised structure that is less pliable than its HIV-1 counterpart [13]. This stringent degree of structural preservation underscores the enzyme's specificity and poses challenges for inhibitor development, as there is limited room for structural alterations without compromising functionality [16]. Inhibitor design strategies and challenges The development of HTLV-1 PR inhibitors is fundamentally based on structure-based drug design, which utilizes high-resolution crystal structures of the enzyme bound to known inhibitors or substrate analogues. These structures reveal the dimensions and physicochemical properties of the active-site cleft, specificity pockets, and hydrophobic interaction regions, which are exploitable for inhibitor design [5]. One of the primary challenges in HTLV-1 PR inhibitor design is the enzyme's exceptional structural rigidity and narrow substrate specificity [8]. Unlike the more structurally pliable HIV-1 PR, which allows broader inhibitor design and adaptability, the inherent rigidity of HTLV-1 PR severely limits the chemical space for effective inhibitors, posing a unique challenge for targeted drug discovery. This inflexibility, although beneficial for enzyme accuracy, imposes significant limitations on the variety and adaptability of potential inhibitor designs [5]. Historical perspective and initial approaches Initial efforts in inhibitor design focused on targeting the active site using substrate analogues. Researchers tested both octapeptidic and tetrapeptidic inhibitors that mimic the natural substrates of HTLV-1 PR. While these inhibitors demonstrated some level of activity, their potency was often compromised due to subtle structural differences between HTLV-1 and HIV-1 PRs [36]. Recent advancements in research have focused on utilising both rational drug design and structural biology to develop effective inhibitors for HTLV-1 PR. The varied potency, with Indinavir exhibiting only minimal inhibition, highlights the fundamental and novel challenge of translating HIV-1 PR inhibitors directly to HTLV-1 therapeutics, necessitating a novel, HTLV-1-specific approach. The effectiveness of FDA-approved HIV-1 PR inhibitors, including darunavir (DRV) and Indinavir, against HTLV-1 PR has been demonstrated to vary in potency, with Indinavir exhibiting only minimal inhibition (Ki = 62.7 μM). DRV demonstrates greater inhibitory activity (Ki = 0.8 μM) [5,37]. Furthermore, structural analogues of DRV have been synthesised, achieving low nanomolar potency, with some compounds, such as PU6, reaching a Ki of 0.03 μM, a marked improvement over the parent compounds [38]. The absence of cross-reactivity underscores the importance of designing inhibitors tailored to the unique structural features of HTLV-1 PR. The varied potency of HIV-1 inhibitors, such as Indinavir and DRV, against HTLV-1 PR, along with the general lack of effective cross-reactivity, starkly underscores the importance of designing inhibitors tailored to the unique structural features of HTLV-1 PR. Rational drug design methodologies against HTLV-1 PR Rational drug design techniques have taken centre stage in the development of HTLV-1 PR inhibitors. This method typically begins by identifying the primary substrate sequence that the enzyme acts upon, followed by the iterative design and evaluation of inhibitors that mimic the transition state of the natural cleavage reaction. Researchers have conducted systematic studies on truncation and the incorporation of non-natural amino acid substitutions into inhibitor molecules. For example, systematic modifications of HTLV-1 PR hexapeptidic inhibitors have provided insights into enhancing binding potency while overcoming the pitfalls associated with enzyme flexibility [36]. Early strategies borrowed from HIV-1 drug discovery, employing substrate mimetics and transition-state analogues such as statine-based inhibitors and hydroxyethylamine dipeptide isosteres, which were designed to exploit similarities in the protease mechanism [39]. However, the distinct substrate specificity and binding pocket architecture of HTLV-1 PR often rendered these inhibitors significantly less potent, if not ineffective, against the HTLV-1 enzyme [40]. High-resolution crystallographic studies have enabled structure-based drug design targeting unique features of the HTLV-1 PR active site, especially the S3 binding subsite. Computer-aided molecular docking and pharmacophore modelling have guided the synthesis and optimisation of novel compounds, yielding candidates with tailored interactions to the specific geometry and residue composition of HTLV-1 PR [17]. We previously reported the design, expression, and characterisation of a novel recombinant fusion protein comprising HTLV-1 PR linked to human Fcγ1, produced in a CHO cell system. The fusion molecule aims to serve as both a therapeutic target, by identifying inhibitors, and a vaccine candidate, by leveraging Fc-mediated immune responses, particularly cross-presentation and T cell activation. Structural and functional analyses confirmed proper folding, enzymatic activity, and glycosylation, supporting its potential for drug development and vaccine design against HTLV-1-associated diseases [4]. Modern inhibitor design is significantly aided by computational techniques, such as molecular docking and molecular dynamics simulations, which provide detailed insights into inhibitor binding modes, energetics, and the dynamic behaviour of inhibitor–enzyme complexes. These methods pinpoint key residue interactions, unbinding pathways, and residence time within the catalytic pocket [8]. Nonetheless, these successes are limited and variable, reinforcing that direct translation of HIV-1 inhibitors to HTLV-1 has generally been unsuccessful [41]. As a result, there is an urgent demand for inhibitors specifically designed to match the unique structural features and substrate needs of HTLV-1 PR [42]. Meeting this demand would lead to significant improvements in patient outcomes, including reductions in the incidence and progression of ATLL and HAM/TSP, thereby alleviating the suffering of millions of HTLV-1-infected individuals worldwide. Challenges in inhibitor efficacy and resistance development The enzyme's delicate conformational balance presents a double-edged sword. While it leaves little room for error in inhibitor design, it also suggests that well-tailored inhibitors might be less susceptible to resistance mutations. However, the inherently high mutational pressure in viral enzymes means that resistance remains a potential threat, as indicated by the limited success in repurposing HIV inhibitors for HTLV-1 [8]. Selective inhibition of HTLV-1 PR faces several challenges rooted in structural biology and enzymology [17]. This contrasts sharply with HIV-1, where resistance mechanisms are extensively characterised and frequently updated, underscoring a critical, novel knowledge gap for HTLV-1 that necessitates focused research to predict and preempt resistance development specifically for this virus [43]. The distinct folding and active-site architecture of HTLV-1 PR distinguish it from other retroviral PRs, limiting the utility of established inhibitors such as ritonavir, KNI-727, and KNI-764 [42]. Rational drug design has increasingly shifted toward the de novo design of molecules that exploit the enzyme's unique features, supported by X-ray structures of both the wild-type enzyme and key mutants (e.g., L40I) [35]. In contrast to HIV-1, the mechanisms of resistance in HTLV-1 PR remain inadequately characterised due to a lack of clinical inhibitor pressure; however, the enzyme's low mutational tolerance implies that resistance may evolve at a slower rate [13]. This inadequate characterisation constitutes a significant limitation to the development of durable HTLV-1 therapies, as understanding resistance pathways is paramount for preventing future clinical failure and ensuring the long-term efficacy of any developed inhibitors. Nevertheless, any robust inhibitor design must anticipate potential resistance, balancing high affinity for the protease with the risk of escape mutations [44]. Integration of computational studies with medicinal chemistry and iterative structure-activity relationship analysis is driving progress toward clinically relevant inhibitors [37,38]. To date, there are no FDA-approved drugs for HTLV-1, and, crucially, the absence of reported clinical trials centred exclusively on HTLV-1 PR inhibitors represents a profound limitation and a significant hurdle to translating preclinical findings into patient benefit [45]. A clear roadmap should be developed, outlining key milestones such as comprehensive toxicity testing, robust pharmacokinetic and pharmacodynamic profiling, and the design of early-phase (Phase I/II) clinical trials specifically for HTLV-1 PR inhibitors, leveraging insights from similar therapeutic development pathways for other retroviruses. The presumptive route to achieving effective treatment for HTLV-1 infection is depicted in Fig. 1. Flowchart detailing the rational drug design process for HTLV-1 PR inhibitors. This flowchart outlines the systematic approach employed in the design and optimisation of inhibitors specifically targeted against HTLV-1 PR. Each step is crucial for ensuring that potential inhibitors can overcome the unique challenges posed by this enzyme's structure. Latency and therapeutic efficacy of HTLV-1 PR inhibitor HTLV-1 utilizes a dynamic equilibrium of proviral latency and intermittent bursts of active transcription to maintain persistent infection and promote the clonal expansion of infected CD4+ T cells [46]. While the virus evades immune surveillance during latent phases, the HTLV-1 protease remains a critical therapeutic target because it is indispensable for the maturation of Gag and Gag-Pol polyproteins required to form infectious virions during de novo infection [46,47]. ​Recent research employing the Timer-of-cell-kinetics-and-activity (Tocky) system has revealed that latency is reversible and characterized by sporadic transcriptional bursts, which can be visualized at a single-cell level using fluorescent timer proteins [48]. This reversible state creates strategic windows for protease inhibitors to block the recruitment of new cells into the viral reservoir, particularly in contexts such as early-stage infection, kick and kill strategies, or the prevention of mother-to-child transmission [49,50]. Advanced machine learning methods, such as TockyConvNet, further enhance the analysis of these temporal dynamics by identifying specific cell populations where enhancers like CNS2 actively regulate the frequency of viral transcription [48]. HTLV-1 PR inhibitor pharmacokinetic and pharmacodynamic challenges The lack of approved HTLV-1 PR inhibitors reflects current challenges, including rapid metabolism, poor cell permeability, and distribution issues associated with hydrophobic or peptidic structures [51,52]. Additionally, achieving high selectivity to prevent off-target effects on human enzymes further complicates their development [53]. Comparative considerations; HTLV-1 PR vs. HIV-1 PR Despite both being aspartic proteases vital to their viruses, HTLV-1 and HIV-1 PRs differ in substrate specificity, structure, and inhibitor response. Variations in binding grooves, key residues, flap dynamics, and cavity size affect substrate and drug interactions, requiring distinct inhibitory strategies [29]. Table 4 summarises key comparative points between the two proteases and emphasises the different approaches taken to inhibit HTLV-1 PR. It identifies the challenges associated with repurposing HIV-1 PR inhibitors and highlights the progress made in designing more tailored substrate analogues. Table 4Comparative analysis of various inhibitor types targeting HTLV-1 PR.Table 4FeatureHTLV-1 PRHIV-1 PRSubsite determinantsS3, P1/P1' highly influentialMore flexible, multiple determinantsInhibitor toleranceLow (few effective cross-inhibitors)High (many potent inhibitors)Mutational flexibilityLow sequence context is criticalModerate-high, higher mutation rateResistance evolutionLittle clinical evidence; likely slowWell-characterised, rapid upon therapyInhibitor typeTraditional HIVPoor efficacy against HTLV-1 except Indinaviraatazanavir, darunavir, ritonavir, saquinavirOctapeptidicModerate efficacy, but complex synthesisbNATetrapeptidicPromising activity with non-natural amino acidscNANA: Not applicable.aStructural differences, particularly in the flap region.bHigh molecular weight and potential off-target effects.cRequires delicate balance in molecular modifications. Comparative analysis of various inhibitor types targeting HTLV-1 PR. NA: Not applicable. Structural differences, particularly in the flap region. High molecular weight and potential off-target effects. Requires delicate balance in molecular modifications. Impact of HTLV-1 PR inhibitor on HTLV-1-associated diseases The therapeutic significance of the HTLV-1 protease lies in its ability to influence the clinical course of both malignancy and inflammatory disorders [4]. ​In HAM/TSP, where tissue infiltration by infected cells drives neuroinflammation, reducing the production of active viral components through protease inhibition could potentially slow disease progression [54]. ​Combining protease inhibitors with other antiretroviral agents or immunomodulators might improve outcomes, especially since ATL is often resistant to conventional chemotherapy [55]. Prospects and future directions in HTLV-1 PR inhibitor discovery Advancing HTLV-1 PR inhibitor development remains an ambitious yet critical endeavour, requiring continuous integration of biochemical, structural, and computational data [17]. Despite the slow clinical progress compared to HIV-1 PR inhibitors, the strategic targeting of HTLV-1 PR holds great promise for both therapeutic intervention and as a model for the broader class of aspartic protease inhibitors [7,39]. Continued multidisciplinary research is necessary to translate enzymatic insights into clinically viable antiviral agents that can reduce the disease burden associated with HTLV-1 infection. Future directions in HTLV-1 PR inhibitor research emphasise exploring a diverse chemical space. While peptidic and peptidomimetic inhibitors have been developed, non-peptidic scaffolds with improved drug-like properties, such as cyclic and aromatic hydrocarbons at the termini, are gaining prominence due to their favourable hydrophobic interactions and increased stability [17]. Structural biology and high-resolution techniques Advances in high-resolution X-ray crystallography, nuclear magnetic resonance (NMR), detailed kinetic assays, cryo-electron microscopy (cryo-EM), and rational lead optimisation will continue to inform structure-based drug design, with increasing reliance on virtual screening and machine learning to prioritise potent, selective candidates [38] and detailed insights into binding site accommodation, key protein–ligand interactions, and regions for optimisation, such as the S1 and S1′ subsites [5]. Further elucidation of resistance pathways, substrate processing nuances, and allosteric regulatory mechanisms will be key to ensuring long-term therapeutic efficacy and preventing future emergence of resistance [37,44]. Such high-resolution techniques will enable precise mapping of ligand-binding sites and the dynamic behaviour of the flap region, thereby facilitating the rational design of inhibitors that match the enzyme's unique conformational adjustments [45]. Furthermore, structure-based optimisation facilitates the identification of privileged chemical scaffolds—such as transition-state analogues, C2-symmetric pyrrolidines, and non-peptidic sulfonamides—with potential for low toxicity and favourable pharmacokinetics [31]. These molecules offer a starting point for future in vitro and in vivo validation, progressing towards candidates suitable for clinical investigation [5]. Computational modelling and simulations The application of molecular dynamics simulations and quantum mechanics/molecular mechanics (QM/MM) approaches has already shed light on the unbinding process of HTLV-1 PR inhibitors. Recent studies simulating the unbinding pathways of potent versus weak inhibitors offer critical insights into key interactions, including the roles of Asp32 and His66 in maintaining inhibitor binding. Docking studies show that designed sulfonamide-peptoid inhibitors, such as SP-4 and SP-5, demonstrate nanomolar inhibitory constants (47.69 nM and 1.23 nM, respectively), along with robust drug-likeness scores and favourable ADME profiles [17]. These findings may be utilised to predict new binding conformations and design molecules that leverage these interactions for enhanced efficacy [8]. Such enhanced efficacy would manifest as a 100-fold increase in binding affinity and a 50-fold reduction in viral replication in relevant in vitro models, which are critical thresholds for advancing compounds into preclinical stages and validating the computational predictions [56]. Emerging therapeutic approaches In parallel with structural and computational studies, novel therapeutic approaches such as allosteric inhibition are gaining traction. By targeting regions of the enzyme outside the active site, allosteric inhibitors can modulate HTLV-1 PR activity without directly competing with the substrate. This strategy may prove particularly useful in circumventing the resistance issues associated with traditional active-site inhibitors [8,16]. Concluding remarks Prospects for HTLV-1 PR inhibitor discovery are optimistic, driven by advances in rational drug design grounded in structural and molecular insights, innovative chemical scaffolds, and molecular dynamics simulations. HTLV-1 PR remains a challenging yet promising target for the development of antiviral drugs. A thorough understanding of its molecular functions, structural determinants, and the intricacies of inhibitor binding will be essential in paving the way toward effective treatments for HTLV-1-associated diseases. Innovative strategies include recombinant Fc-fusion proteins as novel engineered constructs that enhance drug delivery and immune response, to enhance inhibitor bioavailability, and structural studies of drug-resistant mutants to prevent clinical failure. Also, combination therapies targeting multiple viral components, including the Rex regulatory protein, may prove essential given HTLV-1's ability to persist in dormant reservoirs. Additionally, leveraging advances in CRISPR-based screening as a powerful genetic tool for systematically identifying therapeutic targets and single-particle cryo-EM as an advanced imaging technique revealing high-resolution structural details of biological molecules could accelerate the identification of allosteric binding sites and high-affinity HTLV-1 PR inhibitors. Finally, as the structural and mechanistic understanding of HTLV-1 PR matures, collaboration between virologists, computational biologists, and medicinal chemists will be critical to transform this enzyme from a biological curiosity into a clinically actionable target. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Availability of data and materials Not applicable. Funding This research received no specific grant from any funding agency in the public, university, commercial, or not-for-profit sectors. CRediT authorship contribution statement Sanaz Ahmadi Ghezeldasht: Investigation, Writing – original draft. Raheleh Miri: Investigation, Writing – original draft. Seyed Khosrow Shamsian: Investigation, Writing – original draft. Arman Mosavat: Conceptualization, Data curation, Investigation, Supervision, Validation, Writing – review & editing. Seyed Abdolrahim Rezaee: Conceptualization, Data curation, Investigation, Supervision, Validation, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments The authors would like to express their sincere gratitude to the Vice-Chancellor for Research and Technology, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan, Mashhad, Iran, for their valuable assistance and kind support. We sincerely apologies to the authors whose prominent research could not be cited due to space constraints. Contributor Information Sanaz Ahmadi Ghezeldasht, Email: sanaz.ahmadi@acecr.ac.ir. Raheleh Miri, Email: miri@jdm.ac.ir. Seyed Khosrow Shamsian, Email: Kh.shamsian@jdm.ac.ir. Arman Mosavat, Email: Mosavat@acecr.ac.ir. Seyed Abdolrahim Rezaee, Email: RezaeeR@mums.ac.ir. Abbreviations ATLL: adult T-cell leukaemia/lymphoma; BLV: bovine leukaemia virus; HAM/TSP: HTLV-1-associated myelopathy/tropical spastic paraparesis; HIV-1 PR: human immunodeficiency virus-1 protease; HTLV-1 PR: HTLV-1 protease; HTLV-1: Human T-cell leukaemia virus type 1. References Associated Data Data Availability Statement Not applicable.